FinanceAsianet Newsable
ZVRA stock plunges after EU rejection of Meplyffa
in5points
ZVRA stock fell pre-market after the European Medicines Agency recommended refusal of marketing authorization for Zevra’s Meplyffa.
Meplyffa is a medicine intended for the treatment of Niemann-Pick disease type C.
The stock is heading for its worst day in over five years.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically